Claims
- 1. A method of inhibiting H-2 histamine receptors which comprises administering to an animal in need of inhibition of said receptors in an effective amount to inhibit said receptors a heterocyclic compound of the formula: ##STR16## wherein A is such that there is formed together with the carbon atom shown an unsaturated heterocyclic nucleus, said unsaturated heterocyclic nucleus being a 3-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridine) ring; X.sub.1 is hydrogen, lower alkyl, hydroxyl, trifluoromethyl, benzyl, halogen, amino or ##STR17## X.sub.2 is hydrogen or when X.sub.1 is lower alkyl, lower alkyl or halogen; k is 0 to 2 and m is 2 or 3, provided that the sum of k and m is 3 or 4; Y is oxygen, sulphur or NH; E is NR.sub.2 ; R.sub.1 is hydrogen, lower alkyl or di-lower alkylamino-lower alkyl; and R.sub.2 is hydrogen, nitro or cyano, or a pharmaceutically acceptable addition salt thereof.
- 2. A method of claim 1 in which the heterocyclic compound is administered orally.
- 3. A method of claim 1 in which the heterocyclic compound is administered in a daily dosage regimen of from about 150 mg. to about 1000 mg.
- 4. A method of inhibiting gastric acid secretion which comprises administering to an animal in need thereof in an effective amount to inhibit gastric acid secretion a heterocyclic compound of the formula: ##STR18## wherein A is such that there is formed together with the carbon atom shown an unsaturated heterocyclic nucleus, said unsaturated heterocyclic nucleus being a 3-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridine) ring; X.sub.1 is hydrogen, lower alkyl, hydroxyl, trifluoromethyl, benzyl, halogen, amino or ##STR19## X.sub.2 is hydrogen or when X.sub.1 is lower alkyl, lower alkyl or halogen; k is 0 to 2 and m is 2 or 3, provided that the sum of k and m is 3 or 4; Y is oxygen, sulphur or NH; E is NR.sub.2 ; R.sub.1 is hydrogen, lower alkyl or di-lower alkylamino-lower alkyl; and R.sub.2 is hydrogen, nitro or cyano, or a pharmaceutically acceptable addition salt thereof.
- 5. A pharmaceutical composition to inhibit H-2 histamine receptors comprising a pharmaceutical carrier and in an effective amount to inhibit said receptors a heterocyclic compound of the formula: ##STR20## wherein A is such that there is formed together with the carbon atom shown an unsaturated heterocyclic nucleus, said unsaturated heterocyclic nucleus being a 3-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridine ring; X.sub.1 is hydrogen, lower alkyl, hydroxyl, trifluoromethyl, benzyl, halogen, amino or ##STR21## X.sub.2 is hydrogen or when X.sub.1 is lower alkyl, lower alkyl or halogen; k is 0 to 2 and m is 2 or 3, provided that the sum of k and m is 3 or 4; Y is oxygen, sulphur or NH; E is NR.sub.2 ; R.sub.1 is hydrogen, lower alkyl or di-lower alkylamino-lower alkyl; and R.sub.2 is hydrogen, nitro or cyano, or a pharmaceutically acceptable addition salt thereof.
- 6. A pharmaceutical composition of claim 5 in which the heterocyclic compound is N-cyano-N'-methyl-N"-[2-(3-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridyl)methylthio)ethyl]guanidine.
- 7. A pharmaceutical composition of claim 5 in which the pharmaceutical composition is in the form of a tablet or capsule.
- 8. A pharmaceutical composition of claim 5 in which the heterocyclic compound is present in an amount of from about 50 mg. to about 250 mg.
- 9. A method of claim 1 in which the heterocyclic compound is N-cyano-N'-methyl-N"-[2-(3-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridyl)methylthio)ethyl]guanidine.
Parent Case Info
This is a division of application Ser. No. 010,105 filed Feb. 7, 1979, now U.S. Pat. No. 4,221,802 which is a division of application Ser. No. 847,285 filed Oct. 31, 1977 now U.S. Pat. No. 4,154,844, which is a division of application Ser. No. 765,040 filed Feb. 2, 1977 now U.S. Pat. No. 4,070,475, which is a division of application Ser. No. 637,499 filed Dec. 4, 1975 now U.S. Pat. No. 4,024,271, which is a division of application Ser. No. 450,957 filed Mar. 14, 1974 now U.S. Pat. No. 3,950,333, which is a continuation-in-part of Ser. No. 290,584 filed Sept. 20, 1972 now abandoned, which is a continuation-in-part of Ser. No. 230,451 filed Feb. 29, 1972 now abandoned.
US Referenced Citations (9)
Non-Patent Literature Citations (1)
Entry |
Chem. Abst., 75-118317k (1971). |
Divisions (5)
|
Number |
Date |
Country |
Parent |
10105 |
Feb 1979 |
|
Parent |
847285 |
Oct 1977 |
|
Parent |
765040 |
Feb 1977 |
|
Parent |
637499 |
Dec 1975 |
|
Parent |
450957 |
Mar 1974 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
290584 |
Sep 1972 |
|
Parent |
230451 |
Feb 1972 |
|